AxoGen, Inc. (OTCBB: AXGN), a leading regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, today announced that it will release its financial results for the period ended December 31, 2012, after the close of U.S. financial markets on March 12, 2013.
